查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1654191

美國胰臟癌治療市場規模、佔有率、趨勢分析報告：按類型、治療方法、分銷管道和細分市場預測，2025-2030 年

U.S. Pancreatic Cancer Treatment Market Size, Share & Trends Analysis Report By Type (Exocrine, Endocrine), By Treatment (Chemotherapy, Radiation Therapy, Others), By Distribution Channel, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10個工作天內

價格

美國胰臟癌治療市場的成長與趨勢

根據Grand View Research, Inc.的最新報告，美國胰臟癌治療市場預計到2030年將達到20.1億美元，2025年至2030年期間的複合年成長率為12.02%。

這一市場的發展受到胰腺癌發病率上升、腫瘤學研究資金增加以及 FDA 對新型治療方法的核准。發病率上升、人口老化、治療技術的進步以及強大的醫療保健基礎設施是影響市場的關鍵因素。

胰臟癌是最具侵襲性和致命性的癌症之一，其特徵是存活率低。然而，標靶治療、免疫療法和手術的最新發展正在開創治療這種疾病的新時代。胰臟癌的治療方案包括手術、化療、放射療法以及標靶治療和免疫療法等新興療法。手術切除仍然是唯一的根治性方法，但由於診斷晚期，只有 10%-20% 的患者可以接受手術。化療，特別是以Gemcitabine為基礎的聯合療法（如 FOLFIRINOX）仍然是標準治療方法。同時，針對 KRAS 和 BRCA1/2 等基因突變的標靶治療以及查核點抑制劑等免疫療法也越來越受歡迎。

美國胰臟癌治療市場的一些知名公司包括羅氏、禮來公司、百時美施貴寶、阿斯特捷利康和安進公司。這些公司正在大力投資研發，並正在開發多種新療法。儘管取得了進展，但市場仍面臨一些挑戰。延遲診斷限制了許多患者的治療選擇，而先進的治療費用昂貴。此外，缺乏可靠的生物標記繼續阻礙早期檢測和個人化治療的發展。

美國胰臟癌治療市場未來可能會取得長足發展。精準醫療方法將透過識別可操作的突變實現更個人化的治療。基於人工智慧的早期檢測和治療計畫工具正變得越來越普及，而合作研究舉措正在加速藥物開發和臨床試驗。官民合作關係在解決胰臟癌治療中未滿足的需求方面也發揮著重要作用。

美國胰臟癌治療市場正在呈現出變革性成長的跡象。儘管挑戰依然存在，最尖端科技與創新治療的結合為改善患者治療效果帶來了希望。包括製藥公司、研究人員和醫療保健提供者在內的相關人員正在共同努力，解決受這種毀滅性疾病影響的患者和家庭的關鍵需求。未來十年有望重塑胰臟癌治療格局，並為更好地治療這種疾病提供新的希望和機會。

美國胰臟癌治療市場報告重點

  • 根據類型，外分泌部分在 2024 年美國胰臟癌治療市場中佔據最大收入佔有率，為 43.25%。這項優勢歸功於外分泌型胰臟癌的發生率高，佔胰臟癌的大多數，以及針對此類癌症的標靶治療的進展。
  • 根據治療方法，化療佔據市場主導地位，佔有 43.25% 的佔有率，預計在預測期內仍將保持領先地位。化療，特別是廣泛使用以Gemcitabine為基礎的方案和 FOLFIRINOX，儘管存在抗藥性和副作用等挑戰，但仍有助於治療胰腺癌。
  • 從分銷管道來看，醫院藥房預計將在 2024 年佔據最大的銷售佔有率，達到 46.01%，並繼續引領市場。這是因為醫院在管理複雜的治療方法中發揮重要作用，而且因診斷和治療胰臟癌而住院的患者數量也在增加。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章美國胰臟癌治療市場變數、趨勢與範圍

  • 母市場展望
  • 補貼市場前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 胰臟癌治療分析工具
    • 波特的分析
    • PESTEL 分析

第 4 章美國胰臟癌治療市場：按類型估計和趨勢分析

  • 美國胰臟癌治療市場：類型細分儀表板
  • 美國胰臟癌治療市場：類型變化分析，2024 年與 2030 年
  • 外分泌
  • 內分泌

第 5 章美國胰臟癌治療市場：治療方法的估計和趨勢分析

  • 美國胰臟癌治療市場：治療細分儀表板
  • 美國胰臟癌治療市場：2024 年和 2030 年治療變化分析
  • 化療
  • 放射治療
  • 其他

第 6 章：美國胰臟癌治療市場通路、估計與趨勢分析

  • 美國胰臟癌治療市場：通路細分儀表板
  • 美國胰臟癌治療市場：2024 年和 2030 年分銷管道變化分析
  • 醫院藥房
  • 零售藥局
  • 其他

第7章 競爭格局

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司分類
  • 公司熱圖分析
  • 公司簡介
    • Accuray Incorporated
    • AstraZeneca
    • Novartis AG
    • Pfizer Inc.
    • Genentech, Inc.（F. Hoffmann-La Roche Ltd）
    • Bristol-Myers Squibb Company
    • Ipsen Pharma
    • Eli Lilly and Company
    • Siemens Healthineers AG（Varian Medical Systems, Inc.）
    • Elekta AB
Product Code: GVR-4-68040-499-6

U.S. Pancreatic Cancer Treatment Market Growth & Trends:

The U.S. pancreatic cancer treatment market is anticipated to reach USD 2.01 billion by 2030 and is expected to grow at a CAGR of 12.02% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the rising prevalence of pancreatic cancer, increased funding for oncology research, and FDA approvals for novel therapies. Rising incidence rates, an aging population, therapeutic advances, and robust healthcare infrastructure are key factors influencing the market.

Pancreatic cancer is one of the most aggressive and lethal forms of cancer, characterized by poor survival rates. However, recent developments in targeted therapies, immunotherapies, and surgical procedures are shaping a new era for managing the disease.Treatment options for pancreatic cancer include surgery, chemotherapy, radiation therapy, and emerging therapies such as targeted therapy and immunotherapy. Surgical resection remains the only potential curative option but is viable for only 10-20% of patients due to late-stage diagnosis. Chemotherapy, particularly gemcitabine-based combinations like FOLFIRINOX, continues to be the standard treatment. Meanwhile, targeted therapies focusing on genetic mutations such as KRAS and BRCA1/2 and immunotherapy approaches like checkpoint inhibitors are gaining traction.

Prominent U.S. pancreatic cancer treatment market players include Roche, Eli Lilly and Company, Bristol-Myers Squibb, AstraZeneca, and Amgen Inc. These companies are actively investing in research and development, with several novel therapies in the pipeline.Despite advancements, the market faces several challenges. Late diagnosis limits treatment options for many patients, while the high costs of advanced therapies can be prohibitive. Additionally, the lack of reliable biomarkers continues to hamper early detection and the development of personalized treatments.

Looking forward, the U.S. pancreatic cancer treatment market is poised for significant advancements. Efforts in precision medicine enable more personalized treatments by identifying actionable mutations. Artificial intelligence-based tools for early detection and treatment planning are gaining traction, while collaborative research initiatives are accelerating drug development and clinical trials. Public-private partnerships are also playing a crucial role in addressing unmet needs in pancreatic cancer treatment.

The U.S. pancreatic cancer treatment market is on the cusp of transformative growth. While challenges persist, the integration of cutting-edge technologies and innovative therapies offers hope for improved patient outcomes. Stakeholders, including pharmaceutical companies, researchers, and healthcare providers, are working collaboratively to address the critical needs of patients and families affected by this devastating disease. The next decade promises to reshape the landscape of pancreatic cancer treatment, offering new hope and opportunities for better management of this condition.

U.S. Pancreatic Cancer Treatment Market Report Highlights:

  • On the basis of type, the exocrine segment held the largest revenue share of 43.25% of the U.S. pancreatic cancer treatment market in 2024. This dominance is attributed to the high prevalence of exocrine pancreatic cancer, which accounts for the majority of cases, and advancements in treatment modalities targeting this type.
  • Based on treatment, the chemotherapy dominated the market with a share of 43.25% and is expected to maintain its lead during the forecast period. The widespread use of chemotherapy, particularly gemcitabine-based regimens and FOLFIRINOX, has been instrumental in managing pancreatic cancer, despite challenges such as resistance and side effects.
  • Based on distribution channel, the hospital pharmacies accounted for the largest revenue share of 46.01% in 2024 and are expected to continue leading the market. This is due to the critical role hospitals play in administering complex treatment regimens, coupled with the increasing number of inpatient visits for pancreatic cancer diagnosis and treatment.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Pancreatic Cancer Treatment Market Variables, Trends, & Scope

  • 3.1. Parent Market Outlook
  • 3.2. Ancillary Market Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
      • 3.3.1.1. Rising Prevalence of Pancreatic Cancer
      • 3.3.1.2. Advancements in Modern Therapeutics
      • 3.3.1.3. Growing Investments in Pancreatic Cancer R&D
    • 3.3.2. Market Restraints Analysis
      • 3.3.2.1. High Cost of Advanced Therapies
      • 3.3.2.2. Stringent Regulatory and Reimbursement Challenges
  • 3.4. Pancreatic Cancer Treatment Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. U.S. Pancreatic Cancer Treatment Market: By Type Estimates & Trend Analysis

  • 4.1. U.S. Pancreatic Cancer Treatment Market: Type Segment Dashboard
  • 4.2. U.S. Pancreatic Cancer Treatment Market: By Type Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Exocrine
    • 4.3.1. Exocrine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Endocrine
    • 4.4.1. Endocrine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Pancreatic Cancer Treatment Market: Treatment Estimates & Trend Analysis

  • 5.1. U.S. Pancreatic Cancer Treatment Market: Treatment Segment Dashboard
  • 5.2. U.S. Pancreatic Cancer Treatment Market: By Treatment Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Chemotherapy
    • 5.3.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Radiation Therapy
    • 5.4.1. Radiation Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Pancreatic Cancer Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. U.S. Pancreatic Cancer Treatment Market: Distribution Channel Segment Dashboard
  • 6.2. U.S. Pancreatic Cancer Treatment Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Others
    • 6.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Heat Map Analysis
  • 7.4. Company Profiles
    • 7.4.1. Accuray Incorporated
      • 7.4.1.1. Participant's Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Recent Developments/ Strategic Initiatives
    • 7.4.2. AstraZeneca
      • 7.4.2.1. Participant's Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Recent Developments/ Strategic Initiatives
    • 7.4.3. Novartis AG
      • 7.4.3.1. Participant's Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Recent Developments/ Strategic Initiatives
    • 7.4.4. Pfizer Inc.
      • 7.4.4.1. Participant's Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Recent Developments/ Strategic Initiatives
    • 7.4.5. Genentech, Inc. (F. Hoffmann-La Roche Ltd)
      • 7.4.5.1. Participant's Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Recent Developments/ Strategic Initiatives
    • 7.4.6. Bristol-Myers Squibb Company
      • 7.4.6.1. Participant's Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Recent Developments/ Strategic Initiatives
    • 7.4.7. Ipsen Pharma
      • 7.4.7.1. Participant's Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Recent Developments/ Strategic Initiatives
    • 7.4.8. Eli Lilly and Company
      • 7.4.8.1. Participant's Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Recent Developments/ Strategic Initiatives
    • 7.4.9. Siemens Healthineers AG (Varian Medical Systems, Inc., part of the company)
      • 7.4.9.1. Participant's Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Recent Developments/ Strategic Initiatives
    • 7.4.10. Elekta AB
      • 7.4.10.1. Participant's Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Recent Developments/ Strategic Initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 U.S. Pancreatic Cancer Treatment Market, by country, 2018 - 2030 (USD Million)
  • Table 3 U.S. Pancreatic Cancer Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 4 U.S. Pancreatic Cancer Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 5 U.S. Pancreatic Cancer Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 U.S. Pancreatic Cancer Treatment Market Segmentation
  • Fig. 8 Market Snapshot, 2024
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 14 Porter's Five Forces Analysis
  • Fig. 15 U.S. Pancreatic Cancer Treatment Market: Type movement analysis
  • Fig. 16 U.S. Pancreatic Cancer Treatment Market: Type outlook and key takeaways
  • Fig. 17 U.S. Exocrine pancreatic cancer treatment market estimates and forecasts, 2018 - 2030
  • Fig. 18 U.S. Endocrine pancreatic cancer treatment market estimates and forecasts, 2018 - 2030
  • Fig. 19 U.S. Pancreatic cancer treatment market: Treatment movement analysis
  • Fig. 20 U.S. Pancreatic cancer treatment market: Treatment outlook and key takeaways
  • Fig. 21 U.S. Chemotherapy market estimates and forecasts, 2018 - 2030
  • Fig. 22 U.S. Radiation Therapy market estimates and forecasts, 2018 - 2030
  • Fig. 23 U.S. Others market estimates and forecasts, 2018 - 2030
  • Fig. 24 U.S. Pancreatic cancer treatment market: Distribution Channel movement analysis
  • Fig. 25 U.S. Pancreatic cancer treatment market: Distribution Channel outlook and key takeaways
  • Fig. 26 U.S. Hospital Pharmacies market estimates and forecasts, 2018 - 2030
  • Fig. 27 U.S. Retail Pharmacies market estimates and forecasts, 2018 - 2030
  • Fig. 28 U.S. Others market estimates and forecasts, 2018 - 2030